JUPITER, Fla., March 24, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,673,618 entitled, "Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose" by the United States Patent and Trademark Office ("USPTO").
This new patent provides broader intellectual property rights relating to compositions and methods of developing and producing novel enzymes which efficiently convert different sources of plant biomass (e.g. corn stover, wheat straw and bagasse) to fermentable sugars. These sugars can be used in the production of advanced biofuels and bio-based chemicals.
Methods include processes for degrading plant material using enzyme mixtures and specified enzyme combinations. Enzyme compositions are used to break down specific components of plant biomass (e.g. cellulose, hemi-cellulose, and lignin) into a variety of fermentable sugars.
In addition to claims covering the production of these patented enzymes using Dyadic's C1 Expression System, a wide variety of additional production methods are covered including bacteria, yeast, algae, other fungi and plants.
Dyadic's President and CEO, Mark Emalfarb, stated, "Plant biomass provide a plentiful source of potential energy in the form of sugars that can be utilized to produce advanced biofuels and bio-based chemicals. This latest patent further broadens our family of patents that address the advanced biofuels and bio-based chemicals market. This latest patent also expands our comprehensive intellectual property portfolio further protecting our C1 Expression System, and the products derived therefrom. We anticipate that broadening our rights for these applications will allow us to further attract additional blue chip customers, partners, and collaborators."
This patent is the fourteenth U.S. patent issued to Dyadic adding to its portfolio of 41 international patents, 23 pending international and 10 pending U.S. patent applications which cover various features of Dyadic's proprietary technologies.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.
Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic on the OTC marketplace website at (www.otcmarkets.com/stock/DYAI/quote).
Cautionary Note Regarding Forward-Looking Statements
Certain statements contained in this press release are "forward-looking statements" within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, overall IP portfolio and our ability to attract new customers, partners and collaborators may constitute forward-looking statements. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. If Dyadic does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Factors that could cause results to differ materially include, but are not limited to: (1) whether the patented technology will result in any new products; (2) whether the patented technology will result in any new customers, partners, collaborations or licensing agreements; (3) Dyadic's research and development efforts, (4) Dyadic's ability to successfully enforce its intellectual property rights and (5) other factors discussed in Dyadic's publicly available filings, including the risk factors included in Dyadic's Initial Information and Disclosure Statement filed with the OTC Markets Group on March 11, 2014.
SOURCE Dyadic International, Inc.